A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Medicines designed to treat COVID-19 won't be available for months, so doctors are looking to drugs already approved for treating other diseases. Coronavirus drugs: Where we are and what we know ...

President Trump has pushed the use of hydroxychloroquine for COVID-19. Scientists are still trying to figure out whether it helps.

Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients Families who ate together more often during the pandemic had more positive interactions Masks and smart seating cut ...

However, as the authors acknowledge, future studies to examine the efficacy of interferon beta-1b alone or in combination with other drugs to treat severe or critically ill patients with confirmed ...

Moderna’s Covid-19 vaccine showed 93% efficacy against symptomatic disease through six months, and the company expects to complete its application for full approval from the US Food and Drug ...

COVID-19 drug studies look at repurposed drugs 02:39. Dr. Francis Collins, Director of the National Institutes of Health told 60 Minutes that misinformation about hydroxychloroquine, a drug used ...

Hope against COVID-19: Drug cuts deaths by a third and ... The ACTION trial is “a nationwide trial in the U.S. that is designed to evaluate the efficacy of a single dose of azithromycin ...

NanoViricides believes that the safety and efficacy of this drug could make it a popular choice, as some of the more popular alternative COVID-19 treatments available are either less safe or are ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. As with its ...

In the "war" that the world has been fighting against COVID-19, scientists have been scanning their arsenals of previously used drugs in hopes of finding any that can be used to treat the disease.